
Target-led treatments for lung cancer – are they moving to the next level?
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.
Antibody–drug conjugates may represent a step up from existing therapeutic options, but further optimisation and biomarker analyses are required.
Additional treatment targets and potentially repurposable agents were identified based on chemoradiotherapy response, which could now be explored for further validation.
Global cooperation is needed to improve trial design and expedite new treatments specifically in low- and middle-income countries
Findings from studies show that patient-centred evidence can inform decisions in early-phase cancer research
Randomised trials and real-world data propel the anti-EGFR rechallenge approach towards standard of care, but more solid evidence is needed
Preliminary results revealed that the combination of claudin 18.2/4-1BB bispecific antibody with nivolumab and mFOLFOX was also well tolerated
Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting
Final analyses of the PICCOLO trial confirm the efficacy of the antibody–drug conjugate in recurrent platinum-sensitive ovarian cancer
A small Japanese study provides useful insights on determining the role of these agents in cancer care, but studies in larger, more diverse populations are needed
Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.